Astrana Health (NASDAQ:ASTH) Price Target Cut to $49.00 by Analysts at Bank of America

Astrana Health (NASDAQ:ASTH - Free Report) had its target price lowered by Bank of America from $55.00 to $49.00 in a research note issued to investors on Tuesday morning,Benzinga reports. Bank of America currently has a buy rating on the stock.

A number of other analysts have also recently weighed in on ASTH. Truist Financial dropped their price target on Astrana Health from $59.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday, January 13th. Robert W. Baird reduced their target price on Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a report on Monday. Stifel Nicolaus lowered their target price on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Finally, Macquarie upgraded Astrana Health to a "hold" rating in a research note on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Astrana Health presently has a consensus rating of "Moderate Buy" and a consensus target price of $56.83.

Astrana Health Price Performance

Shares of NASDAQ ASTH traded up $0.41 during midday trading on Tuesday, hitting $27.19. The company had a trading volume of 327,310 shares, compared to its average volume of 244,310. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health has a twelve month low of $23.12 and a twelve month high of $63.20. The business has a 50-day simple moving average of $34.57 and a two-hundred day simple moving average of $44.16. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of 20.92, a price-to-earnings-growth ratio of 1.37 and a beta of 1.20.

Astrana Health (NASDAQ:ASTH - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. Equities research analysts anticipate that Astrana Health will post 1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. PharVision Advisers LLC acquired a new position in shares of Astrana Health during the fourth quarter worth $211,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Astrana Health by 15.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,658 shares of the company's stock valued at $3,300,000 after buying an additional 14,138 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Astrana Health in the 4th quarter valued at about $1,208,000. Two Sigma Investments LP bought a new position in shares of Astrana Health during the 4th quarter valued at approximately $466,000. Finally, Sherbrooke Park Advisers LLC bought a new position in shares of Astrana Health during the 4th quarter valued at approximately $494,000. 52.77% of the stock is owned by institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.